KLK3 and prostate cancer: In order to determine whether N-linked glycosylation alters AR activity, we evaluated the effect of tunicamycin on the expression of Kallikrein 3 (KLK3), which is a direct AR target protein, and also a well-characterized biomarker for prostate cancer and known glycoprotein [32].